Ask VialBase
weight · loss

5-Amino-1MQ

FDA: research-only
Last updated · 2026-04-12

5-Amino-1MQ is a small molecule NNMT inhibitor that preserves and boosts NAD+ levels, leading to more efficient mitochondrial energy production and fat oxidation. It targets metabolic sluggishness at the enzymatic level, making the body burn more calories at rest. Inhibits NNMT (nicotinamide N-methyltransferase), an enzyme often overactive in people with obesity, metabolic disorders, or aging-related fatigue. When NNMT is overactive it drains NAD+ building blocks. By blocking NNMT, 5-Amino-1MQ preserves NAD+ availability, activates energy-generating pathways including fat oxidation and glucose metabolism, and stimulates mitochondrial biogenesis (PMID: 39604638). - Preserves and boosts NAD+ levels for more efficient mitochondrial energy production -

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight —
Half-life —
CAS number —
Route —
Where to buy 5-Amino-1MQ →BioLongevity Labs · save 15% code VIALBASE
02

Research summary

Study Type Year Key Finding
Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Preclinical animal and in vitro study (24-month-old mice, C2C12 myoblasts) 2019 Preclinical only — 24-month-old mice plus C2C12 myoblast cell culture; no human subjects
Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Preclinical animal study (diet-induced obese mice) 2021 Preclinical mouse study only — diet-induced obese mice, no human subjects and no clinical endpoints
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Preclinical animal study (cecal microbiome profiling in diet-induced obese mice) 2022 Preclinical mouse study only — cecal microbiome profiling in diet-induced obese (DIO) mice, no human subjects

Stacks containing 5-Amino-1MQ

Mito-Melt

MOTS-c + 5-Amino-1MQ + GHK-Cu (optional)

Shred

AOD-9604 + MOTS-c + 5-Amino-1MQ

28-day resets featuring 5-Amino-1MQ

03

Sourcing

Current prices

Updated today

10mg

50mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code vialbase15 at checkout

Stocks this compound Third-party tested Public COAs Positive rep

Save 10% with code aewpzbzd at checkout

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
  • Lipid Panel
  • Fasting Glucose
  • Fasting Insulin
DURING CYCLE
  • CMP
  • Fasting Glucose
POST-CYCLE
  • CMP
  • Lipid Panel
  • Fasting Glucose
Safety & Regulatory Status
FDA STATUS research-only

Regulatory status for 5-Amino-1MQ may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule NNMT inhibitor that preserves and boosts NAD+ levels, leading to more efficient mitochondrial energy production and fat oxidation.
How does 5-Amino-1MQ work?
Inhibits NNMT (nicotinamide N-methyltransferase), an en.
How is 5-Amino-1MQ dosed?
Oral: 10-20 mg/day (most common biohacker dose); 50-100 mg/day in some research protocols; Cycle: 4-6 weeks on; Route: Oral. These figures reflect commonly cited research protocols, not medical advice — consult a clinician.
Is 5-Amino-1MQ FDA-approved?
5-Amino-1MQ is a research-only compound and is not FDA-approved. Research-only compound — not FDA-approved for human use; Available through research chemical suppliers; Not yet in clinical trials for general metabolic use.

References

  1. Neelakantan H, Brightwell CR, Graber TG, et al.. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle.. Biochemical pharmacology (2019). PMID: 30753815
  2. Sampson CM, Dimet AL, Neelakantan H, et al.. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice.. Scientific reports (2021). PMID: 33707534
  3. Dimet-Wiley A, Wu Q, Wiley JT, et al.. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.. Scientific reports (2022). PMID: 35013352